Antibody therapy of cancer

Nature Reviews Cancer

Volumn 12, Issue 4, 2012, Pages 278-287

  Scott, Andrew M ^a   Wolchok, Jedd D ^b,c   Old, Lloyd J ^b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CD52 ANTIGEN; CETUXIMAB; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPHRIN RECEPTOR A3; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; OFATUMUMAB; PACLITAXEL; PANITUMUMAB; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SEPRASE; SOMATOMEDIN C RECEPTOR; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY THERAPY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; COLON CANCER; COLORECTAL CANCER; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HODGKIN DISEASE; IMMUNE SYSTEM; LEUKEMIA RELAPSE; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; SEROLOGY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOMODULATION; NEOPLASMS; TISSUE DISTRIBUTION; TUMOR ESCAPE;

EID: 84858785688     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3236     Document Type: Review

References (60)

1. Rettig, W. J. & Old, L. J. Immunogenetics of human cell surface differentiation. Annu. Rev. Immunol. 7, 481-511 (1989). (Pubitemid 19138021)
2. Van den Eynde, B. J. & Scott, A. M. Encyclopedia of Immunology (eds Roitt, D. P. J. & Roitt, I. M.) 2424-2431 (Academic Press, London, 1998).
3. Scott, A. M. et al. A Phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 104, 4071-4076 (2007). (Pubitemid 47181580)
4. An important trial describing the antibody targeting of a unique tumour-specific conformational receptor epitope in cancer patients and highlighting the relevance of early phase clinical trial design in antibody development.
5. Hughes, B. Antibody-drug conjugates for cancer: poised to deliver? Nature Rev. Drug Discov. 9, 665-667 (2010).
6. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Rev. Immunol. 10, 317-327 (2010).
7. Nelson, A. L. et al. Development trends for human monoclonal antibody therapeutics. Nature Rev. Drug Discov. 9, 767-774 (2010).
8. Deckert, P. M. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr. Drug Targets 10, 158-175 (2009).
9. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev. Cancer. 8, 579-591 (2008).
10. Ravetch, J. In vivo veritas: the surprising roles of Fc receptors in immunity. Nature Immunol. 11, 183-185 (2010).
11. Schliemann, C. & Neri, D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 180, 201-216 (2010).
12. Scott, A. M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9, 1639-1647 (2003). (Pubitemid 36554586)
13. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
14. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007). (Pubitemid 47026733)
15. Weiner, G. J. Rituximab: mechanism of action. Semin. Hematol. 47, 115-123 (2010).
16. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Eng. J. Med. 363, 711-723 (2010).
17. A pivotal Phase III trial that led to the approval of ipilimumab for the treatment of patients with metastatic melanoma.
18. Chan, A. C. & Carter, P, J. Therapeutic antibodies for autoimmunity and inflammation. Nature Rev. Immunol. 10, 301-316 (2010).
19. Cheson, B. D. & Leonard, J. P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359, 613-626 (2008).
20. Schoeberl, B. et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31 (2009).
21. Canadas, I. et al. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin. Transl. Oncol. 12, 253-260 (2010).
22. Scartozzi, M. et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr. Opin. Mol. Ther. 12, 361-371 (2010).
23. Vearing, C. et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signalling and downstream responses: potential as EphA3-specific tumour targeting reagents. Cancer Res. 65, 6745-6754 (2005). (Pubitemid 41060712)
24. Fox, N. L. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin. Biol. Ther. 10, 1-18 (2010).
25. Welt, S. et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 12, 1193-1203 (1994). (Pubitemid 24173933)
26. Jungbluth, A. A. et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 100, 639-644 (2003). (Pubitemid 36126105)
27. Wu, A. M. & Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotech. 23, 1137-1146 (2009). (Pubitemid 41486395)
28. Herbertson, R. A. et al. Phase I biodistribution and pharmacokinetic study of Lewis Y targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Can. Res. 15, 6709-6715 (2009).
29. Caron, P. C. et al. A Phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83, 1760-1768 (1994). (Pubitemid 24107898)
30. Scott, A. M. et al. Specific targeting, biodistribution and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma-results of a Phase I trial. J. Clin. Oncol. 19, 3976-3987 (2001). (Pubitemid 32912025)
31. Scott, A. M. et al. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen. Clin. Cancer Res. 13, 3286-3292 (2007). (Pubitemid 46944914)
32. Divgi, C. R. et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl Cancer Inst. 83, 97-104 (1991).
33. Dijkers, E. C. et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586-592 (2010).
34. de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543-549 (2010).
35. Strevel, E. L. & Siu, L. L. Cardiovascular toxicity of molecularly targeted agents. Eur. J. Cancer 45, 318-331 (2009).
36. Asnacios, A., Naveau, S. & Perlemuter, G. Gastrointestinal toxicities of novel agents in cancer therapy. Eur. J. Cancer 45, 332-342 (2009).
37. Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
38. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
39. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
40. An important study demonstrating the lack of efficacy of wild-type EGFR-specific antibody cetuximab in patients with colorectal cancer harbouring KRAS mutations. This led to the approval of cetuximab only in patients with wild-type KRAS colorectal cancer.
41. Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008). (Pubitemid 351171687)
42. Leach, D. R., Krummel, M. F. & Allison J. P. Enhancement of antitumor immunity by CTLA-4. Science 271, 1734-1736 (1996).
43. The first report of the enhancement of antitumour immunity following CTLA4 blockade.
44. Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821 (2010).
45. Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
46. Heiss, M. M. et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer 127, 2209-2221 (2010).
47. Boland, W. K. & Bebb, G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther. 9, 1199-1206 (2009).
48. Chen, S. et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 23, 1538-1547 (2005).
49. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
50. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
51. Kirkwood, J. M. et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26, 3445-3455 (2008).
52. Taylor, C. et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 15, 5133-5143 (2007). (Pubitemid 47502081)
53. Pillay, V., Gan, H. K. & Scott, A. M. Antibodies in oncology. N. Biotech. 28, 518-529 (2011).
54. Beck, A., Wurch, T., Bailly, C. & Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. Nature Rev. Immunol. 10, 345-352 (2010).
55. Pillay, V. et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Oncogene. 11, 448-458 (2009).
56. Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003). (Pubitemid 46606207)
57. This important study demonstrated the impact that FcγR polymorphisms have on the efficacy of rituximab in patients with follicular lymphoma, and highlights the importance of ADCC in the efficacy of rituximab.
58. Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789-1796 (2008).
59. Bibeau, F. et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122-1129 (2009).
60. Ferris, R. L., Jaffee. E. M. & Ferrone, S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28, 4390-4399 (2010).